These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 16767920)

  • 21. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
    Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S
    J Immunother; 2006; 29(1):87-94. PubMed ID: 16365604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral treatment with ACCUTANE does not increase measures of anhedonia or depression in rats.
    Ferguson SA; Cisneros FJ; Hanig JP; Berry KJ
    Neurotoxicol Teratol; 2007; 29(6):642-51. PubMed ID: 17933491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
    Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
    Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
    Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
    Vuoristo MS; Vihinen P; Skyttä T; Tyynelä K; Kellokumpu-Lehtinen P
    Anticancer Res; 2009 May; 29(5):1755-9. PubMed ID: 19443399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients.
    Nicolini A; Mancini PA; Ferrari P; Anselmi L; Sagripanti A; Carpi A
    Biomed Pharmacother; 1996; 50(8):344-9. PubMed ID: 8952853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunomodulatory potential of natural compounds in tumor-bearing mice and humans.
    Pan P; Huang YW; Oshima K; Yearsley M; Zhang J; Arnold M; Yu J; Wang LS
    Crit Rev Food Sci Nutr; 2019; 59(6):992-1007. PubMed ID: 30795687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy.
    Recchia F; Cesta A; Rea S
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):135-43. PubMed ID: 16767920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study.
    Recchia F; De Filippis S; Rosselli M; Saggio G; Fumagalli L; Rea S
    Int J Oncol; 2002 Jun; 20(6):1275-82. PubMed ID: 12012010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
    Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
    Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.